Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc A Pfeffer

Showing results (411-420 of 520) with videos related to

Pageof 52
Sort By:
European Journal of Heart Failure|December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Heart Journal|January 26, 2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and functionMaria Amigoni, Alessandra Meris, Jens Jakob Thune, et al.
European Journal of Heart Failure|July 26, 2024
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MIFinnian R Mc Causland, Martina M McGrath, Brian L Claggett, et al.
American Journal of Nephrology|July 12, 2018
Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant RecipientsAndrew Bostom, Andreas Pasch, Tracy Madsen, et al.
Heart (British Cardiac Society)|April 30, 2017
Streamlining cardiovascular clinical trials to improve efficiency and generalisabilityFaiez Zannad, Marc A Pfeffer, Deepak L Bhatt, et al.
Circulation. Heart Failure|June 12, 2024
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI TrialCarmine G De Pasquale, Brian Claggett, Karola Jering, et al.
Circulation|February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
European Journal of Preventive Cardiology|October 15, 2025
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapibJean-Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
Circulation|July 28, 2010
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or bothAnne-Catherine Pouleur, Ebrahim Barkoudah, Hajime Uno, et al.
Circulation. Heart Failure|May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Pageof 52

Showing results (411-420 of 520) with videos related to

Sort By:
Pageof 52
European Journal of Heart Failure|December 26, 2006
Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARMEldrin F Lewis, Gervasio A Lamas, Eileen O'Meara, et al.
European Heart Journal|January 26, 2007
Mitral regurgitation in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: prognostic significance and relation to ventricular size and functionMaria Amigoni, Alessandra Meris, Jens Jakob Thune, et al.
European Journal of Heart Failure|July 26, 2024
Acute changes in kidney function and outcomes following an acute myocardial infarction: Insights from PARADISE-MIFinnian R Mc Causland, Martina M McGrath, Brian L Claggett, et al.
American Journal of Nephrology|July 12, 2018
Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant RecipientsAndrew Bostom, Andreas Pasch, Tracy Madsen, et al.
Heart (British Cardiac Society)|April 30, 2017
Streamlining cardiovascular clinical trials to improve efficiency and generalisabilityFaiez Zannad, Marc A Pfeffer, Deepak L Bhatt, et al.
Circulation. Heart Failure|June 12, 2024
Safety and Tolerability of Angiotensin Receptor-Neprilysin Inhibitor Initiation in High-Risk Acute Myocardial Infarction Relative to Care Setting: A Subgroup Analysis of the PARADISE-MI TrialCarmine G De Pasquale, Brian Claggett, Karola Jering, et al.
Circulation|February 16, 2006
Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) ProgramEileen O'Meara, Tim Clayton, Margaret B McEntegart, et al.
European Journal of Preventive Cardiology|October 15, 2025
Future myocardial infarction after an acute coronary syndrome and pharmacogenetic response to dalcetrapibJean-Claude Tardif, Marc A Pfeffer, Simon Kouz, et al.
Circulation|July 28, 2010
Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or bothAnne-Catherine Pouleur, Ebrahim Barkoudah, Hajime Uno, et al.
Circulation. Heart Failure|May 1, 2023
Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI TrialKarola S Jering, Brian L Claggett, Marc A Pfeffer, et al.
Pageof 52